Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- EMD Serono Snags US license for Tesamorelin From Theratechnologies
- Eben Tessari submits: Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...
- External links 2008-10-31
Additional Resources
- Theratechnologies Learns from the FDA that its Tesamorelin Clinical Program is Moving in the Right Direction.
- MONTREAL, QUEBEC, Sep 11, 2007 CCNMatthews via COMTEX -- Theratechnologies (TSX:TH) announced today that it has learned from the US Food and Drug Administration FDA that, based on the information known today, the tesamorelin (TH9507) clinical dev MONTREAL, QUEBEC, Sep 11, 2007 CCNMatthews via COMTEX --...
- Research articles 2007-09-11
- Theratechnologies Receives Special Protocol Assessment From FDA for Second Pivotal Phase 3 Trial With TH9507.
- MONTREAL, QUEBEC, Aug 23, 2006 CCNMatthews via COMTEX -- Theratechnologies (TSX:TH) today announced a Special Protocol Assessment SPA from the U. S. Food and Drug Administration for the design of its second pivotal Phase 3 trial evaluating TH9507 MONTREAL, QUEBEC, Aug 23, 2006 CCNMatthews via COMTEX...
- Research articles 2006-08-23
- Theratechnologies: Last Patient Treated in Pivotal TH9507 Trial.(Clinical report)
- MONTREAL, QUEBEC, Oct 25, 2006 CCNMatthews via COMTEX -- Theratechnologies (TSX:TH) announced today that it has completed the efficacy phase (26 weeks of treatment) of its first Phase 3 clinical trial testing TH9507 in HIV-associated lipodystrophy. MONTREAL, QUEBEC, Oct 25, 2006 CCNMatthews via COMTEX -- ...
- Research articles 2006-10-25
- Theratechnologies: Last Patient Treated in First Pivotal TH9507 Study.(Clinical report)
- MONTREAL, QUEBEC, May 2, 2007 CCNMatthews via COMTEX -- Theratechnologies (TSX:TH) announced today that the last patient has completed 52 weeks of treatment in its first Phase 3 clinical study testing TH9507 in HIV-associated lipodystrophy. The Com MONTREAL, QUEBEC, May 2, 2007 CCNMatthews via COMTEX --...
- Research articles 2007-05-02
- Theratechnologies Learns from the FDA that its Tesamorelin Clinical Program is Moving in the Right Direction
- Theratechnologies (TSX: TH) announced today that it has learned from the US Food and Drug Administration FDA that, based on the information known today, the tesamorelin (TH9507) clinical development program is moving in the right direction.
- Research articles 2007-09-11
- Theratechnologies: Last Patient Treated in Pivotal TH9507 Trial
- Theratechnologies (TSX: TH) announced today that it has completed the efficacy phase (26 weeks of treatment) of its first Phase 3 clinical trial testing TH9507 in HIV-associated lipodystrophy. The Company is now proceeding to assemble and refine the data with a view to locking the database in December. Once these...
- Research articles 2006-10-25
- Theratechnologies Receives Special Protocol Assessment From FDA for Second Pivotal Phase 3 Trial With TH9507
- Theratechnologies (TSX: TH) today announced a Special Protocol Assessment SPA from the U. S. Food and Drug Administration for the design of its second pivotal Phase 3 trial evaluating TH9507 for the treatment of HIV-associated lipodystrophy. Company plans call for the new Phase 3 trial to start in the...
- Research articles 2006-08-23
- Theratechnologies: Last Patient Treated in First Pivotal TH9507 Study
- Theratechnologies (TSX: TH) announced today that the last patient has completed 52 weeks of treatment in its first Phase 3 clinical study testing TH9507 in HIV-associated lipodystrophy. The Company expects to be in a position to present top-line, 52-week results at an appropriate venue later this year. This...
- Research articles 2007-05-02
- University of Washington to Conduct Clinical Trial with Theratechnologies' TH9507: NIH Providing US $2.6 Million to Finance the Project.
- MONTREAL, QUEBEC, Mar 28, 2006 CCNMatthews via COMTEX -- (TSX:TH) The University of Washington in Seattle, with support from the National Institutes of Health NIH, is conducting a clinical trial investigating the effects of Theratechnologies' TH9 MONTREAL, QUEBEC, Mar 28, 2006 CCNMatthews via COMTEX -- (TSX:TH)...
- Research articles 2006-03-28
- University of Washington to Conduct Clinical Trial with Theratechnologies' TH9507: NIH Providing US $2.6 Million to Finance the Project
- MONTREAL -- (TSX:TH) The University of Washington in Seattle, with support from the National Institutes of Health NIH, is conducting a clinical trial investigating the effects of Theratechnologies' TH9507 on cognitive function in healthy older adults and older adults with mild cognitive impairment.
- Research articles 2006-03-28
- Theratechnologies: An Overlooked Canadian Biotech Selling at Cash
- Theratechnologies (THTCF.PK) is an overlooked biotech stock trading essentially for the amount of cash on its balance sheet. You are essentially getting the company and its obesity fighting drug for free. It is unlikely this condition will persist for long, particularly since the company announced on 10/27/08 that...
- External links 2008-12-08
- Theratechnologies: Movin' On Up
- Theratechnologies (THTCF.PK) announced this week that the 52 week data from its confirmatory Phase III trial of its obesity fighting drug, Tesamorelin, showed that the drug was safe and effective. The data also matched up with 52 week data from its first Phase III trial. The data blew away...
- External links 2008-12-18
- Toronto Stock Exchange Halt Notice: Canadian Real Estate Investment Trust Unit, Theratechnologies Inc., Provident Energy Units.
- NOVEMBER 26, 2001 The following issues have been halted today: Company CANADIAN REAL THERATECHNOLOGIES PROVIDENT ENERGY ...
- Research articles 2001-11-26
- Market Regulation Services Resumption Notice: EXFO Electro-Optical Engineering Inc.; Theratechnologies Inc.
- TORONTO, ONTARIO, Feb 3, 2004 CCNMatthews via COMTEX The following issues will resume trading today: Company EXFO Theratechnologies ...
- Research articles 2004-02-03
- Theratechnologies lands $10M milestone
- The FDA has accepted Theratechnologies#039s NDA for tesamorelin, a treatment of excess abdominal fat in HIV patients with lipodystrophy. The acceptance triggers a $10 million milestone payment from partner EMD Serono as part of their collaboration agreement. Release
- News items 2009-08-13
- Rockin Stocks for January 8, 2008.
- M2 PRESSWIRE-9 January 2008-Financialbusinessnews.us: Rockin Stocks for January 8, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:08012008 Boston, MA -- International Water-Guard Industries Inc. (TSX VENTURE: IWG); Bonaventure Enterprises Inc. (TSX VENTURE: BVT); SearchHelp, Inc. (OTCBB: SHLP); Advent Software, Inc. (NASDAQ: ADVS); TeleTech...
- Research articles 2008-01-09
- National Computer Systems Announces Acquisition of Delstar Computer Services
- MINNEAPOLIS--BUSINESS WIRE--Aug. 27, 1996-- National Computer Systems, Inc. (NASDAQ/NMS - NLCS), through its wholly owned Canadian subsidiary, today announced that it has acquired the Montreal-based Delstar Systemes Informatique, formally a division of Theratechnologies Inc., of Montreal. Delstar will become a division of NCS's wholly owned Canadian subsidiary. ...
- Research articles 1996-08-27
- << Previous
- page 1 of 1
- Next >>
